Organic Active Ingredients TRIZ Cases

A stepped daily telmisartan dose helps control canine hypertension over time, including refractory cases with incomplete response.

Cationic liposomes protect JFK-targeting siRNA from degradation and improve tumor radiosensitivity through nanoparticle delivery.

Small activating RNA targets the HMBS promoter to raise gene expression and enzyme activity, offering faster porphyria treatment with fewer risks.

Controlled oral dosing of a PI3Kδ hemifumarate inhibitor reduces liver, gastrointestinal, and blood toxicities while supporting longer treatment.

A dual-network hydrogel combines covalent and ionic crosslinking to improve toughness, drug stability, and sustained local release.

Functionalized Tymovirus VLPs improve stability, cancer targeting, and intracellular delivery of imaging or therapeutic cargo with reduced toxicity.

Sustained-release polymer drug particles on balloon coatings target lumen strictures to reduce recurrence and repeated interventions.

Combining a PLK1 inhibitor with anti-angiogenic therapy helps inhibit metastatic cancer progression and improve response and survival outcomes.

Substituted salicylamide compounds improve PAD4 inhibition by tuning molecular substituents, helping treat cancer and autoimmune disorders.

A PEG-propylene glycol naproxen fill raises soft gel drug loading without corrosive pH adjustment, enabling smaller capsules and simpler manufacturing.

Targeted carboxylation of psilocybin alters 5-HT2A and 5-HT1A receptor activity to reduce adverse effects while preserving therapeutic efficacy.

Chemically modified hyaluronan forms cross-linked hydrogels that resist rapid clearance and extend use in therapy, cell delivery, and 3D culture.

A CSF-1R inhibitor suppresses M2 macrophages to remodel the tumor microenvironment and boost checkpoint drug efficacy with lower toxicity.

An oil-based sapropterin suspension blocks oxygen exposure, stays homogeneous, and enables easier pediatric dosing without mixing or rinsing.

By stabilizing Nrf2 in glial cells, a DYRK1A inhibitor suppresses neuroinflammation and improves transplanted neuron survival.

Targeted amino acid substitutions shift TNF binding toward TNFR1 over TNFR2, preserving tumor vasculature permeabilization while reducing side effects.

CDR mutations tune EGFR antibody affinity to preserve tumor-cell potency while reducing normal-tissue toxicity in ADC therapy.

Selective CAR peptide targeting concentrates hydrocortisone at injured endothelium to reduce off-target effects and improve survival.

A stepwise pyrazolo[1,5-a]pyrimidine synthesis route improves large-scale TRK inhibitor production through controlled coupling and intermediate formation.

Novel small molecules selectively inhibit MAP4K1 to enhance immune response and support treatment of cancer and viral infection.

Novel camptothecin ADC compounds use tailored linkers and substituents to improve tumor targeting, stability, efficacy, and safety.

A preservative-free oxymetazoline ophthalmic formulation stabilizes long-term storage while lifting eyelids to treat ptosis without surgery.

Separate pH-buffered semaglutide and cagrilintide chambers prevent particle formation during injection while enabling stable combined delivery.

A tailored heterologous UGT boosts conversion of 4-hydroxybenzyl alcohol to gastrodin, reducing multi-enzyme complexity and improving yield.

Formula (1) lipid compounds raise nucleic acid encapsulation and delivery efficiency, offering a non-viral route beyond gene size and immunogenicity limits.

Formula I compounds selectively inhibit CDK8 and CDK19 to modulate gene expression and expand therapeutic options for cancer.

Engineered immune cells combine tumor antigen targeting with prodrug-converting enzymes to boost local cancer killing while limiting toxicity.

Crystalline menin inhibitor forms disrupt the menin-MLL interaction, lowering oncogene expression and promoting cell differentiation in leukemia.

Protein-induced crystallization uses human serum albumin to control aripiprazole crystal form and habit while avoiding harmful solvents.

Exon 68-targeted antisense oligonucleotides bypass USH2A vector size limits by modulating splicing to restore usherin expression.

Substituent-tuned quinazolines improve kinase inhibition while balancing selectivity for EGFR-mutant and other cancer targets.

Treprostinil treatment for interstitial lung disease helps slow pulmonary function decline and improve forced vital capacity.

Crystalline acid salts of an FGFR inhibitor improve handling, storage stability, dissolution, and bioavailability for cancer drug formulation.

Controlled nanofiltration separates HPBCD isomers by substitution range, enabling more selective cholesterol chelation and delivery than crude mixtures.

Combining a PLK1 inhibitor with anti-angiogenic therapy helps slow metastatic cancer progression and improve response outcomes.

A cell-free primase-polymerase process produces high-fidelity closed linear DNA for safer gene delivery and scalable therapeutic manufacturing.

Specific dsRNA motifs with phosphorothioate and 2′-deoxy modifications improve RNAi gene silencing for therapeutic use.

A direct single enteric coating stabilizes omeprazole in acid without an intermediate layer, reducing residual volatile excipients.

Triplet-triplet annihilation lets photosensitizers use far-red light for high-yield photolysis with deeper tissue penetration and lower phototoxicity.

Tumor-targeting NIR dye conjugates deliver therapeutic or diagnostic agents to cancer cells while reducing toxicity to healthy tissue.

An rAAV-delivered anti-VEGF polypeptide plus RNA interference sustains ocular anti-angiogenic activity while reducing injection burden.

Non-viral mobile genetic elements enable stable integration of large transgenes into immune cells while avoiding viral safety and immunogenicity issues.

An amorphous suvorexant-polymer dispersion improves solubility and bioavailability while maintaining practical formulation stability.

Controlled Ullmann and Buchwald coupling replaces microbial culturing to make high-purity farnesyl dibenzodiazepinones faster and at lower cost.

A membrane-separated metformin core and sitagliptin outer layer balance rapid onset with sustained release to improve glycemic control.

pH-sensitive enteric coatings and dispersion matrices protect rapamycin from gastric degradation and improve oral uptake in dogs and cats.

A pH 3-5.5 peptide amide formulation uses minimal excipients to improve stability, low-dose injection safety, and manufacturability.

Targeted cyclopenta[c]pyrrole derivatives inhibit ABHD6 to support treatment of inflammatory and neurological disorders with reduced central side effects.

Selective binding to the TYK2 JH2 pseudokinase domain reduces JAK2 off-target effects while preserving treatment efficacy in autoimmune disease.

N-acylhydrazones compete for physiological metal ions to curb protein oligomerization and oxidative stress in degenerative aggregopathies.

GalNAc-conjugated siRNA targets hepatocyte AGT mRNA to improve hypertension treatment while reducing side effects from conventional drugs.

Separate cationic and anionic chambers enable stable nanoparticle storage and rapid mixing before delivery, improving spleen-targeted cell uptake.

A crystalline enantiopure deuterium-enriched bupropion improves therapeutic efficacy while reducing side effects linked to racemic formulations.

Rapidly disintegrating oral corticosteroid formulations improve GI mucosal contact and treat inflammation with minimal systemic exposure.

A hydrophobic polymer matrix with a pH modifier helps upadacitinib tablets resist moisture while maintaining extended-release dissolution and low impurities.

For lower-risk MDS after ESA failure, telomerase inhibition with imetelstat can extend transfusion-free intervals and reduce transfusion need.

Electrostatic assembly of cationic artificial nucleic acids enables miR-143 delivery into suspended hematologic cancer cells to inhibit the K-RAS network.

Small RNAs with a GCCGGG core bind multiple FIPV genes to suppress replication and improve feline infectious peritonitis treatment.

An alkaline buffered diclofenac potassium oral solution in stick packs resists oxidative degradation while remaining palatable and ready to use.

Local co-administration of plasminogen activator and hyaluronidase improves fibrosis injection efficacy and speeds contracture relief.

A bioerodible ocular insert uses polymer diffusion and erosion to maintain stable vorolanib levels with low systemic exposure.

Tuning cationic lipid ratio and pKa in lipid nanoparticles improves intracellular nucleic acid delivery while limiting toxicity.

A thermosensitive mucoadhesive hydrogel sustains local immunostimulant release after tumor ablation to limit recurrence and metastasis.

Specific crystalline forms of a diaminopyrimidine P2X3 antagonist improve solubility, dissolution, stability, absorption, and safety.

Hydrocarbyl ester derivatives improve oral bioavailability while preserving AMPA receptor calcium-permeability inhibition for seizure and pain treatment.

Nebulized LNP formulations preserve CFTR mRNA integrity and encapsulation for targeted tracheobronchial and lung delivery in cystic fibrosis.

Exosomes carrying regenerative microRNA improve damaged tissue viability and function while avoiding immune rejection and teratoma risks.

Mild Lewis acid coupling enables stereospecific cannabinoid synthesis with high purity and yield while minimizing THC by-products.

Isoxazole-3-carboxamide derivatives inhibit enteroviruses, including pleconaril-resistant strains, while maintaining low CYP3A4 induction.

Scheduled low-dose THC inhalation keeps analgesia effective while limiting psychoactive effects and pharmacokinetic variability.

Selective KRAS G12C inhibition is combined with immunotherapy or pathway inhibitors to boost tumor killing while limiting on-target toxicity.

Equatorially modified polymer-linked cGMP multimers improve PKG and CNGC inhibition at lower doses while protecting photoreceptor cells.

A heterogeneous palladium catalyst enables recovery and reuse in AR antagonist intermediate synthesis while reducing catalyst residues and cost.

A Formula (I) compound targets the key IPF bottleneck by going beyond disease slowing to reduce lung fibrosis and improve lung function.

Vanadium compounds such as BMOV selectively kill SLC26A2-expressing cancer cells, enabling more precise treatment of solid tumors.

A single S-(1) taxane diastereoisomer improves oral bioavailability, crosses the blood-brain barrier, and counters P-gp drug resistance.

Targeting EED with an azaheteroaryl compound disrupts PRC2 and inhibits EZH2 function to address resistance in neoplastic disease treatment.

Selective tetrahydropyrrolocyclic OX-2 antagonists are tuned to cross the blood-brain barrier and treat insomnia and depression.

By recruiting BTK to ubiquitin ligase, bifunctional compounds drive proteasomal degradation and address C481S inhibitor resistance.

Sequence mutations remove frameshift start codons in FKRP constructs, boosting expression and restoring α-dystroglycan glycosylation.

By modulating TDP-43 intron 6 splicing, this case reduces cytoplasmic aggregation while preserving nuclear TDP-43 function in ALS and FTLD.

SELEX-selected aptamers target ICAM-1 to block rhinovirus attachment while preserving binding in shorter oligonucleotide sequences.

Good's buffers solvate hydrophobic lignin in water without derivatization or toxic solvents, enabling biocompatible biomedical and antimicrobial use.

A single-source vegetable lipid blend balances high DHA and other PUFAs with improved oxidative stability for longer shelf life.

Microprecipitated HPMCAS dispersion stabilizes Compound 1 in amorphous form, improving solubility, processability, and oral bioavailability.

A topical Formula (I) compound suppresses bovine teat papillomas, reducing milking obstruction and secondary infection risk.

Targeting extracellular MT1A with antibodies reduces islet and liver inflammation, improves glucose tolerance, and may slow disease progression.

Modified antisense oligonucleotides lower Ataxin 2 mRNA and protein to address SCA2, ALS, and parkinsonism linked to toxic expression.

A two-layer chewing gum separates gum base from water-soluble ingredients to improve cannabinoid release, chew texture, and flavor.

A water-insoluble fiber matrix speeds nicotine release in a compact saliva-permeable pouch, improving discreet craving relief.

Formula-based TNIK inhibitor analogs improve Wnt pathway targeting while aiming to limit off-target kinase effects in cancer and fibrosis.

Low-solubility benzothiazole pamoate and palmitate salts enable sustained dopamine release, reducing dosing frequency and level fluctuations.

An in situ triflic anhydride-DMF route delivers high-purity ruxolitinib without chromatography, while form G improves solubility and stability.

CNV profiling in CNTN4 and related mGluR genes helps identify ADHD patients likely to respond to fasoracetam with fewer stimulant drawbacks.

A mirror-image superoxide dismutase mimetic improves safety over enzyme therapies, enabling higher dosing and faster administration.

CDK2/4/9 inhibitors promote neutrophil maturation to prevent neutropenia in rhG-CSF-nonresponsive patients while avoiding leukemia risk.

Blocking LDL binding to liver LDLR before dosing redirects gene therapy payloads toward non-liver tissues and reduces hepatotoxicity.

Locamidazole targets inflammatory and metabolic dysfunction in CKD to improve muscle strength, bone density, and treatment consistency.

Localized catechin treatment improves sexual arousal, lubrication, orgasm, and pain relief without systemic hormone side effects.

Biodegradable dendrimer and dendron carriers improve nucleic acid delivery stability while enabling controlled payload release at the target site.

Combining mesdopetam with PPIs improves gastric motility and acid suppression to relieve GERD symptoms faster with fewer side effects.

Substituted imidazo[1,2-b]pyridazine compounds improve CDK12/13 inhibition to drive antiproliferative and apoptotic effects in cancer cells.

Modified ANGPTL4-targeting siRNA conjugates improve nuclease stability and delivery specificity while lowering ANGPTL4 for metabolic regulation.

Novel heterocyclic TYK2 inhibitors improve selectivity over other JAK subtypes, lowering side effects while enabling brain penetration.

Immediate-release oral formulations use excipient-compatible composition design to improve myeloma treatment response while limiting side effects.

Novel Formula I glucocorticoid receptor agonists expand treatment options for autoimmune and inflammatory diseases with targeted therapeutic activity.

Targets stress-driven glucocorticoid damage by using RITA to preserve hippocampal neural stem cells and support treatment of CNS disorders.

Selective blood-concentrating immunophilin binders improve CNS mTOR inhibitor delivery while limiting systemic toxicity and immunosuppression.

Pyrazolo-heteroaryl derivatives improve ATR inhibition in tumors with elevated ATR expression by disrupting DNA repair pathways.

Structural tuning of tetrahydroisoquinolinylmethylbenzamide MOR agonists preserves pain relief while lowering respiratory depression, tolerance, and addiction.

Co-processed excipients replace multi-excipient pre-blends in feeder-limited continuous tablet manufacturing, improving flowability and bulk density.

A hydrophobic organogel implant controls active-agent release independent of physiologic solubility while remaining biodegradable and biocompatible.

Targeting TREM2 with specific antibodies reduces efferocytosis and tumor-supporting macrophage activity while preserving normal tissue repair.

Grignard-based synthesis and purification cut Lemborexant impurities below 1.0 mass % while improving yield for industrial production.

Modified apolipoprotein fragment nanoparticles concentrate therapeutic agents at macrophage-rich sites while limiting systemic toxicity.

Small-molecule ENPP1 inhibitors block cGAMP hydrolysis to preserve innate immune signaling against cancer, infection, and related disorders.

Non-immunogenic proteins such as rice protein reduce CNS inflammation, edema, and macrophage infiltration to support neurological recovery.

A bupropion-cysteine molecular complex stabilizes bupropion against degrading excipients while preserving practical pharmaceutical formulation.

A bifunctional heterocyclic compound recruits E3 ligase to degrade KRAS G12V, G12D, and G12C, aiming to improve pancreatic cancer treatment.

Selective 12-LOX inhibitors treat lupus by blocking inflammatory eicosanoid pathways, offering a targeted alternative to broad immunosuppression.

A solid biopterin formulation avoids oxidation during storage and is mixed with a carrier only before intravenous administration.

A CRISPR-Cas agent targets RHOP23H or NR2E3G56R mutant alleles to inactivate toxic proteins in retinal cells without HDR.

Balanced fat, fiber, and protein levels help support dogs with cancer while reducing chemotherapy-related gastrointestinal upset.

Selective CDK9 inhibitor compounds improve cancer treatment efficacy while reducing off-target toxicity from activity beyond CDK9.

Stabilizing polymers keep naporafenib amorphous, improving oral solubility, dissolution, bioavailability, and scale-up stability.

Selective S1P1 and optional S1P5 modulation improves therapeutic effect while limiting side effects from broad sphingosine-1-phosphate receptor activation.

A monocyclic β-lactam prodrug uses host-mediated activation to treat pneumonia caused by carbapenem-resistant Gram-negative bacteria.

A staged halogenation, oxidation, substitution, reduction, and ring-forming route simplifies pilocarpine intermediate production with high purity and yield.

Shortened closed-system TIL expansion with IL-2, OKT-3, APCs, and cryopreservation cuts manufacturing time for refractory NSCLC treatment.

2-substituted benzyloxy phosph(on)ate prodrugs improve oral bioavailability and liver distribution for sustained treatment delivery.

By inhibiting APT1, ML-348 restores intracellular trafficking and BDNF transport, improving neuronal function in Huntington's disease.

Chemically modified oligonucleotides improve nuclease stability, cell uptake, and dystrophin transcript splicing for muscular dystrophy.

A single oral GnRH antagonist plus hormone add-back tablet maintains bioequivalence while limiting bone loss, hyperplasia risk, and dosing burden.

Reverse phase chromatography controls QS-21 purity and 2018 component content to reduce crude extract waste while maintaining bioactivity.

Heterocyclic GLP-1 agonists modify peptide structure to restore insulinotropic activity and improve glucose homeostasis in T2DM.

rAAV-delivered GM3 synthase isoforms restore ganglioside biosynthesis in the brain to address severe neurological symptoms of GM3S deficiency.

By disrupting Aurora A conformation, these inhibitors break Aurora A-MYCN stabilization and drive rapid MYCN loss in MYCN-driven cancers.

Concentrated betalain formulations raise the betalain-to-sugar ratio, resist clumping, and dissolve well for oral symptom relief without caffeine.

Selective small-molecule JAK1/Tyk2 inhibitors suppress inflammatory pathways while avoiding JAK2-linked hematopoietic and coagulation side effects.

A nitrate-free, low-sugar betalain composition boosts hematocrit and erythropoietin while lowering lactate, heart rate, and exertion.

Stable HCl crystalline forms replace an unusable amorphous state, improving temperature and humidity resistance for consistent motilin drug formulations.

Hybridized QSAR-guided pyridinylpyrazole derivatives improve PLK1 inhibition selectivity while restraining cancer cell proliferation.

Wet-granulated rivaroxaban tablets form a stable oral suspension that avoids crushing, improves dose accuracy, and supports pediatric use.

ASGPR-targeted oligonucleotide conjugates silence PD-L1 in liver cells to restore T cell activity while limiting systemic autoimmune effects.

New CFTR modulator compounds aim to treat more mutation types while improving tolerance and reducing respiratory distress.

A bicyclic RET inhibitor improves selectivity and activity while addressing resistance that limits current multi-kinase cancer therapies.

Ultrasonic mesh aerosolization replaces heating to avoid carbonyl byproducts while delivering stable nanoemulsions with encapsulated actives.

A gel-forming blend of glycosaminoglycans, alginate, and N-acetylglucosamine protects gastric mucosa while avoiding sucralfate safety limits.

Low-GWP HFA-152a and HFO-1234ze(E) propellants help salbutamol inhalers maintain stability and drug delivery while reducing climate impact.

Helicase-primase inhibition helps tricyclic HSV compounds treat resistant TK-deficient strains with fewer adverse effects.

Higher-dose oral pridopidine addresses chorea, bradykinesia, and coordination deficits in Huntington's disease with measurable motor improvement.

P2X4R antagonist compounds reduce inflammation and infarct size in stroke and myocardial reperfusion injury without thrombolytic bleeding risk.

N-linked cyclic pyridine derivatives improve cellular cGAS inhibition and selectivity while reducing off-target effects and cytotoxicity.

Oxidizing ovatodiolide into the Ova-Oxy derivative improves solubility and absorption while retaining strong cytotoxicity across cancer cell lines.

Isoxazole and oxadiazole KCNT1 inhibitors improve selective channel control to reduce neuronal excitability and seizure frequency.

Optimized crospovidone, sodium lauryl sulfate, and copovidone improve deferasirox tablet solubility, flow, and water disintegration.

Tryptophan or tyrosine stabilizes liquid neurotoxin formulations without animal proteins, avoiding reconstitution and lowering contamination risk.

Sequence-specific antisense oligomers suppress GFRAL expression to block GDF15 signaling and alleviate cachexia symptoms.

Resistant dextrin keeps pyrroloquinoline quinone dissolved in acidic or hard-water beverages, preventing deposition and preserving stability.

A salbutamol, HFC-152a, and ethanol composition improves inhaler aerosol stability and fine particle delivery to deep lung regions.

A 2′-O-methyl antisense oligonucleotide suppresses stimulated ICAM-1 expression while limiting toxicity, immunostimulation, and cost.

Boosting Zscan4 expression lengthens telomeres and corrects chromosome abnormalities without relying on telomerase-linked cancer risk.

Local glucocorticoids treat epithelial infections in ear, udder, and uterus while preserving microbial flora and reducing antibiotic reliance.

Novel heteroaromatic carboxamides improve plasma kallikrein selectivity and metabolic stability while supporting oral bioavailability and safety.

Targeted CD19 ADC delivery localizes a glucocorticoid receptor agonist to B-cell malignancies, reducing steroid toxicity while sustaining apoptosis.

Combining lumateperone with a nitric oxide donor improves psychosis, depression, and anxiety treatment in resistant CNS cases.

Novel base-modified cytidine nucleotides improve leukemia treatment tolerability while retaining activity against cytarabine resistance.

Structural fatty acid modifications preserve endogenous bioactivity while improving stability, activity, and delivery for inflammatory and pain-related disorders.

Novel ionizable lipids self-assemble into nanoparticles that raise RNA encapsulation efficiency and improve intracellular delivery to target sites.

Combining M1R activation with M3R inhibition targets CHRM1 and CHRM3 to curb colorectal cancer proliferation more effectively than monotherapy.

A multi-drug neurorestoration composition addresses poor blood-brain barrier delivery while promoting neurogenesis, remyelination, and stroke recovery.

Buffered, mammalian-free cell delivery formulations keep pH and osmolarity stable, prevent settling, and support accurate dosing during storage.

CDK12 inhibition with bicyclic amines blocks HR gene restoration, helping HR-deficient tumors stay sensitive to PARP and DNA-damage therapies.

Daily oral AZD9833 dosing improves estrogen receptor degradation in ER-positive breast cancer and helps address resistance seen with current SERDs.

5-methoxymethyl and 5-hydroxymethyl phenethylamines modulate serotonin receptors to treat inflammation with less generalized immunosuppression.

Antibody-guided STING agonist ADCs improve local immune activation while limiting systemic toxicity in cancer treatment.

Localized bioresorbable implants release steroids in sinus or nasal tissue over months, reducing trauma, systemic side effects, and compliance burden.

An alkaline meloxicam composition uses hydrophilic polymer and alkalizing agents to improve solubility, lower Tmax, and support acute pain treatment.

A quercetin, vitamin B3, vitamin C, and zafirlukast regimen targets neuroinflammation, mitochondrial dysfunction, and lung decline in ALS.

A bilayer levocarnitine-trimetazidine tablet limits air exposure, improving hygroscopicity, content uniformity, and stability.

A lecithin-galactomannan oral powder enables dry dosing or quick suspension in minimal water, improving taste, swallowability, and adherence.

Hetero-bifunctional compounds recruit mutant LRRK2, including G2019S, to cereblon ligases for selective ubiquitination and degradation.

High-affinity anti-TMEFF1 antibodies target follistatin domains to deliver cytotoxic drugs more precisely to cancer cells.

A sustained-release befiradol profile keeps peak plasma levels below 15 ng/mL after 4 hours to treat movement disorders with less dizziness and nausea.

A cured high-molecular-weight PEO matrix extends oral ketamine release to sustain antidepressant effect with fewer dissociative side effects.

Partial visual cycle inhibition via RBP4-TTR modulation reduces toxic bisretinoid buildup in the retinal pigment epithelium for dry AMD.

Targeting the RAC1 network, this compound aims to slow neurodegenerative disease progression while strengthening learning and memory.

Defined HVR sequences improve anti-CD3 antibody binding and stability, helping extend half-life and make tumor targeting more consistent.

Multi-stage enzymatic hydrolysis, UV treatment, and magnetic-field processing improve active ingredient absorption for immunity support and fatigue relief.

Response-inhibiting agents at the cannula insertion site reduce inflammation, coagulation, and encapsulation to extend reliable insulin delivery.

High-solubility purine and pyrimidine solutions enable smaller-volume oral or tube dosing with faster reconstitution and fewer dosing errors.

Sigma-2 receptor antagonists block Aβ oligomer binding to preserve synapses and reduce neuronal toxicity in early Alzheimer's disease.

Oral CD47-SIRPα blocker plus azacitidine improves AML and MDS treatment while limiting anemia, thrombocytopenia, and severe toxicity.

Phthalate polymer dispersions and lyophilization turn oily ITI-007 into a stable solid form with improved solubility and humidity resistance.

An immediate-release MAOI paired with delayed-release tryptamine improves bioavailability, extends action, and reduces dosing variability.

Asymmetric hydrogenation with Ru or Rh chiral phosphine catalysts improves JAK inhibitor yield and enantiomeric purity for therapeutic use.

A macrocyclic ALK/ROS1 inhibitor treats solid tumors and CNS metastases while sparing TRK activity to reduce cognitive and other CNS side effects.

iRNAs drive RISC-mediated CD274/PD-L1 transcript cleavage to counter immune evasion and restore anti-tumor responses.

High-load apalutamide solid dispersions with HPMCAS or poly(meth)acrylate enable one swallowable tablet while maintaining bioequivalence.

A pharmaceutical composition combines powdered hemp seed, soy lecithin, and cannabis to create a stable emulsion.

Novel ATR kinase inhibitor compounds utilize stereoisomers and salts to block protein activity.

Selective p38 MAP kinase inhibitors reduce toxicity while maintaining anti-inflammatory activity in asthma and COPD treatments.